|
1
|
Nagakubo D, Taira T, Kitaura H, et al:
DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in
cooperation with ras. Biochem Biophys Res Commun.
231:509–513. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Annesi G, Savettieri G, Pugliese P, et al:
DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral
sclerosis complex. Ann Neurol. 58:803–807. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller DW, Ahmad R, Hague S, et al: L166P
mutant DJ-1, causative for recessive Parkinson’s disease, is
degraded through the ubiquitin-proteasome system. J Biol Chem.
278:36588–36595. 2003.
|
|
4
|
Martinat C, Shendelman S, Jonason A, et
al: Sensitivity to oxidative stress in DJ-1-deficient dopamine
neurons: an ES-derived cell model of primary Parkinsonism. PLoS
Biol. 2:e3272004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moore DJ, Zhang L, Troncoso J, et al:
Association of DJ-1 and parkin mediated by pathogenic DJ-1
mutations and oxidative stress. Hum Mol Genet. 14:71–84. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim RH, Peters M, Jang Y, et al: DJ-1, a
novel regulator of the tumor suppressor PTEN. Cancer Cell.
7:263–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
MacKeigan JP, Clements CM, Lich JD, et al:
Proteomic profiling drug-induced apoptosis in non-small cell lung
carcinoma: identification of RS/DJ-1 and RhoGDIα. Cancer Res.
63:6928–6934. 2003.PubMed/NCBI
|
|
8
|
Hod Y: Differential control of apoptosis
by DJ-1 in prostate benign and cancer cells. J Cell Biochem.
92:1221–1233. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Le Naour F, Misek DE, Krause MC, et al:
Proteomics-based identification of RS/DJ-1 as a novel circulating
tumor antigen in breast cancer. Clin Cancer Res. 7:3328–3335.
2001.PubMed/NCBI
|
|
10
|
Yoshino T, Shiina H, Urakami S, et al:
Bcl-2 expression as a predictive marker of hormone-refractory
prostate cancer treated with taxane-based chemotherapy. Clin Cancer
Res. 12:6116–6124. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi W, Zhang X, Pintilie M, et al:
Dysregulated PTEN-PKB and negative receptor status in human breast
cancer. Int J Cancer. 104:195–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davidson B, Hadar R, Schlossberg A, et al:
Expression and clinical role of DJ-1, a negative regulator of PTEN,
in ovarian carcinoma. Hum Pathol. 39:87–95. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chu EA and Kim YJ: Laryngeal cancer:
diagnosis and preoperative work-up. Otolaryngol Clin North Am.
41:673–695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
15
|
Adelstein DJ, Li Y, Adams GL, et al: An
intergroup phase III comparison of standard radiation therapy and
two schedules of concurrent chemoradiotherapy in patients with
unresectable squamous cell head and neck cancer. J Clin Oncol.
21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hoffman HT, Porter K, Karnell LH, et al:
Laryngeal cancer in the United States: changes in demographics,
patterns of care, and survival. Laryngoscope. 116:1–13. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Denis F, Garaud P, Bardet E, et al: Final
results of the 94-01 French Head and Neck Oncology and Radiotherapy
Group randomized trial comparing radiotherapy alone with
concomitant radiochemotherapy in advanced-stage oropharynx
carcinoma. J Clin Oncol. 22:69–76. 2004. View Article : Google Scholar
|
|
18
|
Forastiere AA, Maor M, Weber RS, et al:
Long-term results of intergroup RTOG 91-11: a phase III trial to
preserve the larynx-induction cisplatin/5-FU and radiation therapy
versus concurrent cisplatin and radiation therapy versus radiation
therapy. J Clin Oncol. 24(Suppl 18): 55172006.
|
|
19
|
Seiwert TY and Cohen EE: State-of-the-art
management of locally advanced head and neck cancer. Br J Cancer.
92:1341–1348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Brockstein B, Haraf DJ, Rademaker AW, et
al: Patterns of failure, prognostic factors and survival in
locoregionally advanced head and neck cancer treated with
concomitant chemoradiotherapy: a 9-year, 337-patient,
multi-institutional experience. Ann Oncol. 15:1179–1186. 2004.
|
|
21
|
Kutter J, Ozsahin M, Monnier P and Stupp
R: Combined modality treatment with full-dose chemotherapy and
concomitant boost radiotherapy for advanced head and neck
carcinoma. Eur Arch Otorhinolaryngol. 262:1–7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kerr JF, Wyllie AH and Currie AR:
Apoptosis: a basic biological phenomenon with wide-ranging
implications in tissue kinetics. Br J Cancer. 26:239–257. 1972.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu XL, Wang ZF, Lei WB, et al: DJ-1: a
novel independent prognostic marker for survival in glottic
squamous cell carcinoma. Cancer Sci. 101:1320–1325. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu XL, Wang ZF, Lei WB, et al:
Tumorigenesis role and clinical significance of DJ-1, a negative
regulator of PTEN, in supraglottic squamous cell carcinoma. J Exp
Clin Cancer Res. 31:942012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sitaram RT, Cairney CJ, Grabowski P, et
al: The PTEN regulator DJ-1 is associated with hTERT expression in
clear cell renal cell carcinoma. Int J Cancer. 125:783–790. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shendelman S, Jonason A, Martinat C, et
al: DJ-1 is a redox-dependent molecular chaperone that inhibits
α-synuclein aggregate formation. PLoS Biol. 2:e3622004.PubMed/NCBI
|
|
27
|
Vasseur S, Afzal S, Tardivel-Lacombe J, et
al: DJ-1/PARK7 is an important mediator of hypoxia-induced cellular
responses. Proc Natl Acad Sci USA. 106:1111–1116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lei W, Jia T, Su Z, et al: Combined effect
of rapamycin and cisplatin on survival of Hep-2 cells in vitro.
Oncol Res. 18:73–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
